Michael Narachi, President and CEO at Orexigen Therapeutics, Inc. (OREX), sold 150,000 shares at $7.66 ($1.1M) on 2012-07-17, disclosed to the SEC on 2012-07-19.
Scheduled sale ($1.1M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.66 | 25,762 | $197K | 17.2% |
| 2 | $7.66 | 124,238 | $952K | 82.8% |
| Total | $7.66 avg | 150,000 | $1.1M | 100% |
| Filing → |
| OREX | SELL | 2012-07-13 | $1.0M | — | Filing → |
| OREX | SELL | 2012-06-29 | $1.3M | — | Filing → |
| AMAG | BUY | 2012-05-29 | $27K | — | Filing → |